Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.

@article{Anderson2006PriorHT,
  title={Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.},
  author={Garnet L. Anderson and Rowan Chlebowski and Jacques E. Rossouw and Rebecca J. Rodabough and Anne Mctiernan and Karen L. Margolis and Anita Aggerwal and J David Curb and Susan Lee Hendrix and F Allan Hubbell and Jamardan Khandekar and Dorothy S Lane and Norman L. Lasser and Ana M. Lopez and Jonell Potter and Cheryl Ritenbaugh},
  journal={Maturitas},
  year={2006},
  volume={55 2},
  pages={103-15}
}
OBJECTIVES To assess the extent to which prior hormone therapy modifies the breast cancer risk found with estrogen plus progestin (E+P) in the Women's Health Initiative (WHI) randomized trial. METHODS Subgroup analyses of prior hormone use on invasive breast cancer incidence in 16,608 postmenopausal women in the WHI randomized trial of E+P over an average… CONTINUE READING